Adam Sherwat

848 total citations · 1 hit paper
11 papers, 397 citations indexed

About

Adam Sherwat is a scholar working on Infectious Diseases, Epidemiology and Virology. According to data from OpenAlex, Adam Sherwat has authored 11 papers receiving a total of 397 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Infectious Diseases, 5 papers in Epidemiology and 4 papers in Virology. Recurrent topics in Adam Sherwat's work include HIV/AIDS drug development and treatment (4 papers), Pharmacological Effects and Toxicity Studies (3 papers) and Bacillus and Francisella bacterial research (2 papers). Adam Sherwat is often cited by papers focused on HIV/AIDS drug development and treatment (4 papers), Pharmacological Effects and Toxicity Studies (3 papers) and Bacillus and Francisella bacterial research (2 papers). Adam Sherwat collaborates with scholars based in United States, Thailand and Uganda. Adam Sherwat's co-authors include Kirk M. Chan‐Tack, Debra Birnkrant, John Farley, Daniel B. Rubin, John T. Brooks, Peter Kim, Patrick R. Harrington, Julian J. O’Rear, LaRee Tracy and Takashi Komatsu and has published in prestigious journals such as New England Journal of Medicine, Gastroenterology and The Lancet Infectious Diseases.

In The Last Decade

Adam Sherwat

11 papers receiving 389 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tecovirimat and the Treatment of Monkeypox — Past, Present, and Future Considerations

2022 121 citations Adam Sherwat, John T. Brooks et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Adam Sherwat United States	9	171	164	163	152	48	11	397
Gong Shen United States	11	349 2.0×	113 0.7×	167 1.0×	86 0.6×	142 3.0×	21	516
Adele Boccuto Italy	15	236 1.4×	98 0.6×	71 0.4×	88 0.6×	16 0.3×	30	439
Jenny Svärd Sweden	9	202 1.2×	178 1.1×	131 0.8×	224 1.5×	14 0.3×	12	731
Ilaria Vicenti Italy	19	670 3.9×	276 1.7×	222 1.4×	123 0.8×	107 2.2×	75	943
Ona Barauskas United States	9	244 1.4×	58 0.4×	183 1.1×	142 0.9×	154 3.2×	15	513
Takeshi Noshi Japan	12	325 1.9×	72 0.4×	851 5.2×	242 1.6×	126 2.6×	24	1.1k
Brenda I. Hernández-Santiago United States	9	307 1.8×	114 0.7×	167 1.0×	143 0.9×	119 2.5×	16	451
Rujuta A. Bam United States	8	471 2.8×	379 2.3×	135 0.8×	141 0.9×	66 1.4×	11	609
Filippo Dragoni Italy	13	238 1.4×	61 0.4×	53 0.3×	29 0.2×	13 0.3×	31	354
Jacqueline Cronin United States	8	746 4.4×	104 0.6×	176 1.1×	149 1.0×	12 0.3×	9	1.0k

Countries citing papers authored by Adam Sherwat

Since Specialization

Citations

This map shows the geographic impact of Adam Sherwat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adam Sherwat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adam Sherwat more than expected).

Fields of papers citing papers by Adam Sherwat

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adam Sherwat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adam Sherwat. The network helps show where Adam Sherwat may publish in the future.

Co-authorship network of co-authors of Adam Sherwat

This figure shows the co-authorship network connecting the top 25 collaborators of Adam Sherwat. A scholar is included among the top collaborators of Adam Sherwat based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adam Sherwat. Adam Sherwat is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

1.

Qi, Xiaojing, Daniel B. Rubin, Simone M. Shurland, et al.. (2024). Flexible Development Programs for Antibacterial Drugs to Address Unmet Medical Needs. Emerging infectious diseases. 30(11). 2227–2230. 1 indexed citations

2.

Sherwat, Adam, John T. Brooks, Debra Birnkrant, & Peter Kim. (2022). Tecovirimat and the Treatment of Monkeypox — Past, Present, and Future Considerations. New England Journal of Medicine. 387(7). 579–581. 121 indexed citations breakdown →

3.

Rubin, Daniel B., Kirk M. Chan‐Tack, John Farley, & Adam Sherwat. (2020). FDA Approval of Remdesivir — A Step in the Right Direction. New England Journal of Medicine. 383(27). 2598–2600. 133 indexed citations

4.

Struble, Kimberly, et al.. (2019). Cobicistat-containing antiretroviral regimens are not recommended during pregnancy. AIDS. 33(6). 1089–1093. 25 indexed citations

5.

Chan‐Tack, Kirk M., Patrick R. Harrington, Suyoung Choi, et al.. (2019). Assessing a drug for an eradicated human disease: US Food and Drug Administration review of tecovirimat for the treatment of smallpox. The Lancet Infectious Diseases. 19(6). e221–e224. 28 indexed citations

6.

Choi, Suyoung, et al.. (2018). Effects of Sorbitol on the Pharmacokinetics of Lamivudine Solution and the FDA's Decision to Increase the Dose of Lamivudine Solution for Pediatric Patients. Clinical Pharmacology & Therapeutics. 104(5). 785–787. 3 indexed citations

7.

Sheikh, Virginia, Jeffrey S. Murray, & Adam Sherwat. (2018). Ibalizumab in Multidrug-Resistant HIV — Accepting Uncertainty. New England Journal of Medicine. 379(7). 605–607. 10 indexed citations

8.

Tracy, LaRee, et al.. (2017). US FDA Perspective on Elbasvir/Grazoprevir Treatment for Patients with Chronic Hepatitis C Virus Genotype 1 or 4 Infection. Clinical Drug Investigation. 37(4). 317–326. 9 indexed citations

9.

Komatsu, Takashi, Adam Sherwat, LaRee Tracy, et al.. (2016). Regulatory Analysis of Effects of Hepatitis C Virus NS5A Polymorphisms on Efficacy of Elbasvir and Grazoprevir. Gastroenterology. 152(3). 586–597. 42 indexed citations

10.

Fuchs, Jonathan D., Magdalena E. Sobieszczyk, Tamra Madenwald, et al.. (2013). Intentions to Use Preexposure Prophylaxis Among Current Phase 2B Preventive HIV-1 Vaccine Efficacy Trial Participants. JAIDS Journal of Acquired Immune Deficiency Syndromes. 63(3). 259–262. 15 indexed citations

11.

Arya, Vikram, Jeffry Florian, Kendall A. Marcus, et al.. (2013). Does an Increase in Serum Creatinine always Reflect Renal Injury? The Case of Stribild®. The Journal of Clinical Pharmacology. 54(3). 279–281. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact